Your Patients Can't Find Alvesco — Here's How to Help

As a prescriber, you chose Alvesco (Ciclesonide) for a reason — likely its favorable oropharyngeal side-effect profile, its prodrug pharmacology, or a patient's documented intolerance to other inhaled corticosteroids. But your patients keep calling back: "My pharmacy doesn't have it."

This is a growing friction point in asthma care. Alvesco is not in a manufacturer shortage, but pharmacy-level availability is inconsistent enough that it disrupts adherence and creates unnecessary administrative burden for your practice. This guide provides practical, actionable steps you and your staff can implement to help patients access their Alvesco prescriptions more reliably.

Current Availability Landscape

Alvesco remains in active production by Covis Pharma and is not listed on the FDA's drug shortage database. The availability gap is driven by:

• Low dispensing volume: Insurance step therapy funnels patients to cheaper ICS options, reducing Alvesco prescriptions at most pharmacies.
• Limited stocking: Pharmacies stock based on demand. With few Alvesco fills per month, most locations don't keep it on shelves.
• Cost considerations: At $150–$420 per inhaler, pharmacies face inventory risk for slow-moving product.
• No generic available: Patent expiry is February 2028. No generic Ciclesonide inhalation has been approved.

The result: patients are sent on a search for a medication that technically exists in the supply chain but isn't readily accessible at the point of care.

Why Patients Can't Find Alvesco

Understanding the patient experience helps shape your response. When a patient brings a new Alvesco prescription to their pharmacy:

1. The pharmacy likely doesn't have it in stock.
2. The pharmacist may suggest switching to a "similar" medication rather than ordering Alvesco — especially if the patient seems uncertain.
3. If the patient asks for a special order, it arrives in 1–2 days — but many patients don't know to ask.
4. Some patients call multiple pharmacies, get frustrated, and either skip doses or give up entirely.

This gap between prescribing and dispensing is where patients fall through the cracks. Proactive guidance from your practice can prevent most of these issues.

5 Steps Providers Can Take

Step 1: Set Expectations at the Point of Prescribing

The single most impactful thing you can do is tell the patient upfront that Alvesco may not be immediately available at their pharmacy. Simple language works:

"Alvesco is a brand-name inhaler that not every pharmacy stocks. If your pharmacy doesn't have it, ask them to special-order it — it usually arrives the next day. You can also use Medfinder to check which pharmacies near you have it right now."

This sets realistic expectations, reduces callback volume, and empowers the patient to advocate for themselves.

Step 2: Direct Patients to Medfinder

Medfinder for Providers is a free tool that lets patients (and your staff) search for pharmacies in their area with Alvesco currently in stock. Consider:

• Adding Medfinder to your after-visit summary for Alvesco prescriptions
• Training front-desk or MA staff to check availability when patients call about fill issues
• Including a link in your patient portal messaging templates

Step 3: Prescribe to Pharmacies That Stock It

If you know certain pharmacies in your area routinely carry Alvesco — or are willing to order it — consider e-prescribing directly to those locations. Mail-order pharmacies through major PBMs are also generally reliable for Alvesco availability.

Build a short list of "Alvesco-friendly" pharmacies for your practice. This can be as simple as a sticky note at the prescribing station or a note in your EHR template.

Step 4: Proactively Submit Prior Authorization

Don't wait for the pharmacy rejection. If you know the patient's plan requires PA for Alvesco, submit it at the time of prescribing. Include:

• Documentation of prior ICS trial and reason for discontinuation (e.g., oral candidiasis, dysphonia)
• Clinical rationale for Ciclesonide's prodrug advantage
• Relevant chart notes from previous visits

PA forms organized by payer are available at PrescriberPoint (prescriberpoint.com).

Step 5: Connect Patients With Savings Programs

Cost is a real barrier, especially for patients with high deductibles or those in the coverage gap. Equip your staff with information about:

• Covis eVoucher Program: Commercially insured patients may pay as low as $0 (no restrictions) or $60 (with restrictions). Details at alvesco.us/savings-card.
• Covis Patient Assistance Program: Free medication for eligible uninsured/underinsured patients. Application available at alvesco.us.
• Discount cards: GoodRx, SingleCare, and Optum Perks may offer discounts for cash-pay patients.

For a patient-friendly overview, share our article on how to save money on Alvesco.

Alternative ICS Options When Alvesco Isn't Accessible

When access barriers are insurmountable — or when clinical equivalence is acceptable — consider these therapeutic alternatives:

• Fluticasone Propionate HFA (generic): Most widely available and affordable ICS. $30–$80. Preferred on most formularies. Ages 4+.
• Budesonide DPI (generic Pulmicort Flexhaler): $30–$60. Good option for patients comfortable with dry powder inhalers. Ages 6+.
• Qvar RediHaler (Beclomethasone): Breath-actuated design, extra-fine particle formulation. $250–$350. Useful for patients with coordination difficulties. Ages 4+.
• Asmanex Twisthaler (Mometasone): Once-daily dosing option for some patients. $200–$350. Ages 4+.

For patients switching from Alvesco due to oropharyngeal side effects on other ICS agents, document this clearly — it supports future PA requests if they need to return to Ciclesonide.

Workflow Tips for Your Practice

Small workflow adjustments can significantly reduce the Alvesco access burden on your practice:

• Create an Alvesco prescribing template in your EHR that includes patient instructions about availability, Medfinder link, and savings program information.
• Flag Alvesco patients for proactive refill outreach 7–10 days before their expected refill date.
• Maintain a pharmacy reference list of locations that reliably stock or order Alvesco in your area.
• Train your staff on common patient questions about Alvesco availability so they can resolve issues without requiring prescriber intervention.
• Use mail-order pharmacy as a default recommendation for stable Alvesco patients — it eliminates most stocking issues.

Final Thoughts

Alvesco is a clinically valuable ICS option, particularly for patients with oropharyngeal intolerance to other inhaled corticosteroids. The access challenges are real but manageable with proactive communication, the right tools, and practice-level workflow adjustments.

The most effective approach combines three elements: setting patient expectations at the point of prescribing, directing them to availability tools like Medfinder, and ensuring they're connected to savings programs that can offset the cost.

For the patient perspective on Alvesco availability, see our companion article: Alvesco shortage update: what patients need to know in 2026.